The Multiple Faces of Non-small Cell Lung Cancer: Targeted Therapies and Recent Developments
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 20 September 2024 | Viewed by 381
Special Issue Editors
Interests: lung cancer; mesothelioma; phase 1 clinical trials; targeted therapies; next generation sequencing
Interests: lung cancer; adjuvant therapy; minimal residual disease; targeted therapies; next generation sequencing; liquid biopsy
Special Issue Information
Dear Colleagues,
Knowledge of biology of Non-small Cell Lung Cancer has increased in the last years. The use of next generation sequencing (NGS) has permitted to divide this disease in many diseases, according to the presence of molecular drivers. For eight of these oncogene-addicted tumours, targeted therapies have been approved: mutations of EGFR, BRAF, MET, KRAS and rearrangements of ALK, ROS1, RET and NTRK have specific tyrosin-kinase inhibitors (TKIs) that have changed the natural history of these diseases. However, innate and acquired resistances are able to limit the activity of TKIs. For this reason, many efforts are ongoing to understand biology of resistances in order to identify further therapeutic approaches. Several new drugs are entering in the therapeutic strategy of many of those types of tumors. Moreover immune-conjugates represents a new option to target tumoral cells with mechanisms of action different from those of TKIs. Finally the use of NGS may identify molecular features for which less is still known without clear indications of therapy. These situations may arise difficulties in identify the correct therapeutic strategy. This Special issue will focus on targeted therapies for NSCLC and on recent developments in term of biology and new drugs in this field.
Dr. Angelo Delmonte
Dr. Alberto Verlicchi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-small cell lung cancer
- tyrosine-kinase inhibitors
- next generation sequencing
- immunoconjugates
- targeted therapies
